Literature DB >> 10027516

Mecamylamine blocks the development of tolerance to nicotine in rats: implications for the mechanisms of tolerance.

S E McCallum1, A R Caggiula, L H Epstein, S Saylor, T Ploskina, A F Sved.   

Abstract

Chronic injections of nicotine in rats produce upregulation of nicotinic cholinergic receptors. It has been proposed that this upregulation is a reflection of receptor desensitization and is the basis of functional tolerance. Mecamylamine, a non-competitive antagonist that blocks activation of nicotinic receptors, does not prevent upregulation produced by nicotine injections. This suggests that receptor activation is not a prerequisite for nicotine-induced receptor upregulation. Therefore, the present experiments tested whether mecamylamine would also fail to prevent the development of tolerance to nicotine. Six daily pairings of mecamylamine (1 mg/kg SC) with nicotine did block the development of tolerance to nicotine-induced antinociception (0.35 mg/kg) and to the ability of nicotine to suppress milk intake (0.66 mg/kg). In another experiment, six daily injections of mecamylamine, when given alone, did not alter the effects of a subsequent, acute injection of nicotine (0.35 mg/kg) in inducing antinociception in rats. There was no evidence that after six pairings of mecamylamine with nicotine, the cues associated with mecamylamine delivery took on conditioned antagonistic properties. These findings suggest that, unlike the receptor upregulation that results from either continuous or repeated nicotine administration, the tolerance following a short series of intermittent nicotine injections is dependent on receptor activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027516     DOI: 10.1007/s002130050842

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  9 in total

1.  Enhanced pain perception prior to smoking cessation is associated with early relapse.

Authors:  Motohiro Nakajima; Mustafa al'Absi
Journal:  Biol Psychol       Date:  2011-08-02       Impact factor: 3.251

2.  Tolerance to nicotine in mice lacking alpha7 nicotinic receptors.

Authors:  C Naylor; D Quarta; C Fernandes; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

3.  Glutamate transporter activation enhances nicotine antinociception and attenuates nicotine analgesic tolerance.

Authors:  Joseph A Schroeder; Katrina F Quick; Paige M Landry; Scott M Rawls
Journal:  Neuroreport       Date:  2011-12-21       Impact factor: 1.837

4.  Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.

Authors:  M D Raleigh; M Pravetoni; A C Harris; A K Birnbaum; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

5.  Sucrose consumption enhances the analgesic effects of cigarette smoking in male and female smokers.

Authors:  Robin B Kanarek; Catherine Carrington
Journal:  Psychopharmacology (Berl)       Date:  2004-01-14       Impact factor: 4.530

6.  Increased spinal dynorphin contributes to chronic nicotine-induced mechanical hypersensitivity in the rat.

Authors:  Chris Lough; Tracey Young; Renee Parker; Shannon Wittenauer; Michelle Vincler
Journal:  Neurosci Lett       Date:  2007-06-08       Impact factor: 3.046

7.  Nicotine physical dependence and tolerance in the mouse following chronic oral administration.

Authors:  Sheri D Grabus; Billy R Martin; Angela M Batman; Rachel F Tyndale; Edward Sellers; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2004-09-10       Impact factor: 4.530

8.  Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse.

Authors:  Sheri D Grabus; Frank Ivy Carroll; Mohamad Imad Damaj
Journal:  Nicotine Tob Res       Date:  2012-05-15       Impact factor: 4.244

Review 9.  Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.

Authors:  Enrique L M Ochoa; Jose Lasalde-Dominicci
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.